The Czarnota Research Team investigated whether pre-treatment T2-weighted magnetic resonance imaging can be used to predict response to neoadjuvant chemotherapy in breast cancer.
Pre-treatment T2-weighted MRI texture features can predict NAC response with reasonable accuracy. The study examined T2 non-contrast images in predicting the treatment response to NAC. They intend to expand the current study cohort to include a higher number of patients to perform more robust validation strategies, including consideration of external validation from a different institution.
Read the full article:
